Safety profiles were generally similar for ataluren and placebo , except for the occurrence of increased creatinine concentrations ( ie , acute kidney injury ) , which occurred in 18 ( 15 % ) of 118 patients in the ataluren group compared with one ( < 1 % ) of 120 patients in the placebo group .